Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;14(5):581-91.
doi: 10.1016/j.cllc.2013.05.002. Epub 2013 Jul 1.

Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies

Joshua Bauml  1 , Rosemarie Mick, Yu Zhang, Christopher D Watt, Anil Vachani, Charu Aggarwal, Tracey Evans, Corey Langer
Affiliations

Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies

Joshua Bauml et al. Clin Lung Cancer. 2013 Sep.

Abstract

Background: Molecular profiling of non-small-cell lung cancer (NSCLC) samples has a profound impact on choice of therapy. However, it is less clear whether EGFR and KRAS mutations are prognostic outside of a trial-based treatment paradigm.

Methods: We performed a retrospective chart review of 513 patients with NSCLC undergoing EGFR and KRAS mutational analysis at the Hospital of the University of Pennsylvania between May 2008 and November 2011. Survival analysis was based on the 376 patients who received systemic treatment, and their survival was determined from the date of initiation of systemic therapy.

Results: The median overall survival (OS) was 30.8 months (95% confidence interval [CI], 24.7-36.9). Neither EGFR mutational status (P = .09) nor KRAS mutational status (0.69) was associated with OS. Female sex (P < .001), never smoker status (P = .01), better performance status (PS) (P < .001), lower Charlson Comorbidity Index (P < .001), and lower age-weighted index (P < .001) were associated with prolonged survival. The presence of bone metastases (P = .001) and liver metastases (P = .004) was also associated with a shortened survival. In a multivariable regression that adjusted for stage, we demonstrated that male gender (P = .002), worse Eastern Cooperative Oncology Group PS (P = .01), metastases to bone (P = .03), and higher age-weighted comorbidity index (P = .001) were independent prognostic factors for shorter survival. EGFR mutation status was not prognostic (P = .85).

Conclusion: In our series, EGFR and KRAS do not function as prognostic determinants for NSCLC.

Keywords: EGFR; KRAS; Non–small-cell lung cancer; Prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT Diagram
Figure 2
Figure 2
Figure 3
Figure 3
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012;62(1):10–29. doi: papers2://publication/doi/10.3322/caac.20138. - PubMed
    1. Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong S-S, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(21):2866–74. doi: papers2://publication/doi/10.1200/JCO.2010.33.4235. - PubMed
    1. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The lancet oncology. 2011;12(8):735–42. doi: papers2://publication/doi/10.1016/S1470-2045(11)70184-X. - PubMed
    1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England journal of medicine. 2004;350(21):2129–39. doi: papers2://publication/doi/10.1056/NEJMoa040938. - PubMed
    1. Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England journal of medicine. 2010;363(18):1693–703. doi: papers2://publication/doi/10.1056/NEJMoa1006448. - PMC - PubMed

Publication types

MeSH terms